<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01540513</url>
  </required_header>
  <id_info>
    <org_study_id>RO11360</org_study_id>
    <nct_id>NCT01540513</nct_id>
  </id_info>
  <brief_title>PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404</brief_title>
  <official_title>PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404
      PET/CT in human brain tumors. This goal will be accomplished by quantifying tumor uptake and
      determining the optimal PET/CT protocol, comparing PET tumor uptake to MRI, and calculating
      tumor dosimetry. The long-term goals of this research are to improve the diagnosis and
      treatment of malignant brain tumors by using radioiodinated NM404
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>tumor-to-background ratios</measure>
    <time_frame>48hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>imaging will be performed at 6hrs, 24hrs and 48 hrs post injection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>I124-NM404 brain metastases or GBM imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of I-124NM404 for imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NM404</intervention_name>
    <description>injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging
Other Names:
PET imaging with I-124 NM404</description>
    <arm_group_label>I124-NM404 brain metastases or GBM imaging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NM404</intervention_name>
    <description>injection of an experimental imaging agent, 5mCi I-124NM404</description>
    <arm_group_label>I124-NM404 brain metastases or GBM imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will have a contrast enhanced brain MRI which          documents
             evidence of primary or metastatic brain tumor or suspected tumor recurrence after
             therapy

          -  Tumor size at least 1.5 cm in greatest axial dimension on MRI. MRI must be obtained
             within 2 months of study inclusion

          -  Adult patients 18 or older

          -  Female patients must not be pregnant or breast feeding and both women of childbearing
             potential, and men, must use appropriate means of contraception and must be
             maintained for at least 45 days after injection of 124I-NM404 Participants must not
             attempt to become pregnant during this time

          -  Platelet count must be ≥ 160,000/µl, Hematocrit must be ≥ 22%, Leukocyte count must
             be ≥ 3,000/µL, Creatinine must be ≤ 2.5 mg/dL, ALT must be ≤ 130 U/L, AST must be ≤
             100 U/L, and urine or serum pregnancy test must be negative for pregnancy

          -  Patient provides informed consent

          -  Karnofsky score ≥ 60

          -  For previously treated brain tumors, targeted brain therapy (radiation or drug) must
             have concluded ≥2 months prior to injection of 124I-NM404

        Exclusion Criteria:

          -  Life expectancy of &lt; 3 months

          -  Allergy to potassium iodide (SSKI or Thyroshield)

          -  Unwilling or unable to complete 3 separate PET/CT imaging sessions of 90 minutes each
             over 3 days

          -  Pregnancy or breast-feeding during time of study and/or anticipated breast feeding at
             any time for 45 days after injection of 124I-NM404.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lance Hall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Hospital and Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Trask, BS</last_name>
    <phone>608-263-9528</phone>
    <email>trask@humonc.wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Trask, BS</last_name>
    </contact>
    <investigator>
      <last_name>Lance Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 17, 2013</lastchanged_date>
  <firstreceived_date>February 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
